Global Specific Antiviral Drugs for COVID-19 Market Research Report 2023

Specific Antiviral Drugs for COVID-19 Market

According to new survey, global Specific Antiviral Drugs for COVID-19 market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Specific Antiviral Drugs for COVID-19 market research.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Specific Antiviral Drugs for COVID-19 market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

Scope of Specific Antiviral Drugs for COVID-19 Market Report

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Specific Antiviral Drugs for COVID-19 Market Size Growth Rate by Type: 2018 VS 2022 VS 2029

1.2.2 Tablet

1.2.3 Injection

1.3 Market by Application

1.3.1 Global Specific Antiviral Drugs for COVID-19 Market Growth by Application: 2018 VS 2022 VS 2029

1.3.2 Mild Symptom Patient

1.3.3 Critically Ill Patient

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2.1 Global Specific Antiviral Drugs for COVID-19 Market Perspective (2018-2029)

2.2 Specific Antiviral Drugs for COVID-19 Growth Trends by Region

2.2.1 Global Specific Antiviral Drugs for COVID-19 Market Size by Region: 2018 VS 2022 VS 2029

2.2.2 Specific Antiviral Drugs for COVID-19 Historic Market Size by Region (2018-2023)

2.2.3 Specific Antiviral Drugs for COVID-19 Forecasted Market Size by Region (2024-2029)

2.3 Specific Antiviral Drugs for COVID-19 Market Dynamics

2.3.1 Specific Antiviral Drugs for COVID-19 Industry Trends

2.3.2 Specific Antiviral Drugs for COVID-19 Market Drivers

2.3.3 Specific Antiviral Drugs for COVID-19 Market Challenges

2.3.4 Specific Antiviral Drugs for COVID-19 Market Restraints

3.1 Global Top Specific Antiviral Drugs for COVID-19 Players by Revenue

3.1.1 Global Top Specific Antiviral Drugs for COVID-19 Players by Revenue (2018-2023)

3.1.2 Global Specific Antiviral Drugs for COVID-19 Revenue Market Share by Players (2018-2023)

3.2 Global Specific Antiviral Drugs for COVID-19 Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Specific Antiviral Drugs for COVID-19 Revenue

3.4 Global Specific Antiviral Drugs for COVID-19 Market Concentration Ratio

3.4.1 Global Specific Antiviral Drugs for COVID-19 Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Specific Antiviral Drugs for COVID-19 Revenue in 2022

3.5 Specific Antiviral Drugs for COVID-19 Key Players Head office and Area Served

3.6 Key Players Specific Antiviral Drugs for COVID-19 Product Solution and Service

3.7 Date of Enter into Specific Antiviral Drugs for COVID-19 Market

3.8 Mergers & Acquisitions, Expansion Plans

4.1 Global Specific Antiviral Drugs for COVID-19 Historic Market Size by Type (2018-2023)

4.2 Global Specific Antiviral Drugs for COVID-19 Forecasted Market Size by Type (2024-2029)

5.1 Global Specific Antiviral Drugs for COVID-19 Historic Market Size by Application (2018-2023)

5.2 Global Specific Antiviral Drugs for COVID-19 Forecasted Market Size by Application (2024-2029)

6.1 North America Specific Antiviral Drugs for COVID-19 Market Size (2018-2029)

6.2 North America Specific Antiviral Drugs for COVID-19 Market Growth Rate by Country: 2018 VS 2022 VS 2029

6.3 North America Specific Antiviral Drugs for COVID-19 Market Size by Country (2018-2023)

6.4 North America Specific Antiviral Drugs for COVID-19 Market Size by Country (2024-2029)

6.5 United States

6.6 Canada

7.1 Europe Specific Antiviral Drugs for COVID-19 Market Size (2018-2029)

7.2 Europe Specific Antiviral Drugs for COVID-19 Market Growth Rate by Country: 2018 VS 2022 VS 2029

7.3 Europe Specific Antiviral Drugs for COVID-19 Market Size by Country (2018-2023)

7.4 Europe Specific Antiviral Drugs for COVID-19 Market Size by Country (2024-2029)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8.1 Asia-Pacific Specific Antiviral Drugs for COVID-19 Market Size (2018-2029)

8.2 Asia-Pacific Specific Antiviral Drugs for COVID-19 Market Growth Rate by Region: 2018 VS 2022 VS 2029

8.3 Asia-Pacific Specific Antiviral Drugs for COVID-19 Market Size by Region (2018-2023)

8.4 Asia-Pacific Specific Antiviral Drugs for COVID-19 Market Size by Region (2024-2029)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9.1 Latin America Specific Antiviral Drugs for COVID-19 Market Size (2018-2029)

9.2 Latin America Specific Antiviral Drugs for COVID-19 Market Growth Rate by Country: 2018 VS 2022 VS 2029

9.3 Latin America Specific Antiviral Drugs for COVID-19 Market Size by Country (2018-2023)

9.4 Latin America Specific Antiviral Drugs for COVID-19 Market Size by Country (2024-2029)

9.5 Mexico

9.6 Brazil

10.1 Middle East & Africa Specific Antiviral Drugs for COVID-19 Market Size (2018-2029)

10.2 Middle East & Africa Specific Antiviral Drugs for COVID-19 Market Growth Rate by Country: 2018 VS 2022 VS 2029

10.3 Middle East & Africa Specific Antiviral Drugs for COVID-19 Market Size by Country (2018-2023)

10.4 Middle East & Africa Specific Antiviral Drugs for COVID-19 Market Size by Country (2024-2029)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11.1 Sanofi

11.1.1 Sanofi Company Detail

11.1.2 Sanofi Business Overview

11.1.3 Sanofi Specific Antiviral Drugs for COVID-19 Introduction

11.1.4 Sanofi Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)

11.1.5 Sanofi Recent Development

11.2 Novartis

11.2.1 Novartis Company Detail

11.2.2 Novartis Business Overview

11.2.3 Novartis Specific Antiviral Drugs for COVID-19 Introduction

11.2.4 Novartis Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)

11.2.5 Novartis Recent Development

11.3 Shanghai Zhongxisanwei

11.3.1 Shanghai Zhongxisanwei Company Detail

11.3.2 Shanghai Zhongxisanwei Business Overview

11.3.3 Shanghai Zhongxisanwei Specific Antiviral Drugs for COVID-19 Introduction

11.3.4 Shanghai Zhongxisanwei Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)

11.3.5 Shanghai Zhongxisanwei Recent Development

11.4 Teva

11.4.1 Teva Company Detail

11.4.2 Teva Business Overview

11.4.3 Teva Specific Antiviral Drugs for COVID-19 Introduction

11.4.4 Teva Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)

11.4.5 Teva Recent Development

11.5 Zydus Cadila

11.5.1 Zydus Cadila Company Detail

11.5.2 Zydus Cadila Business Overview

11.5.3 Zydus Cadila Specific Antiviral Drugs for COVID-19 Introduction

11.5.4 Zydus Cadila Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)

11.5.5 Zydus Cadila Recent Development

11.6 Mylan

11.6.1 Mylan Company Detail

11.6.2 Mylan Business Overview

11.6.3 Mylan Specific Antiviral Drugs for COVID-19 Introduction

11.6.4 Mylan Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)

11.6.5 Mylan Recent Development

11.7 Apotex

11.7.1 Apotex Company Detail

11.7.2 Apotex Business Overview

11.7.3 Apotex Specific Antiviral Drugs for COVID-19 Introduction

11.7.4 Apotex Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)

11.7.5 Apotex Recent Development

11.8 Advanz Pharma

11.8.1 Advanz Pharma Company Detail

11.8.2 Advanz Pharma Business Overview

11.8.3 Advanz Pharma Specific Antiviral Drugs for COVID-19 Introduction

11.8.4 Advanz Pharma Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)

11.8.5 Advanz Pharma Recent Development

11.9 Sun Pharma

11.9.1 Sun Pharma Company Detail

11.9.2 Sun Pharma Business Overview

11.9.3 Sun Pharma Specific Antiviral Drugs for COVID-19 Introduction

11.9.4 Sun Pharma Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)

11.9.5 Sun Pharma Recent Development

11.10 Kyung Poong

11.10.1 Kyung Poong Company Detail

11.10.2 Kyung Poong Business Overview

11.10.3 Kyung Poong Specific Antiviral Drugs for COVID-19 Introduction

11.10.4 Kyung Poong Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)

11.10.5 Kyung Poong Recent Development

11.11 Ipca Laboratories

11.11.1 Ipca Laboratories Company Detail

11.11.2 Ipca Laboratories Business Overview

11.11.3 Ipca Laboratories Specific Antiviral Drugs for COVID-19 Introduction

11.11.4 Ipca Laboratories Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)

11.11.5 Ipca Laboratories Recent Development

11.12 Hanlim Pharmaceutical

11.12.1 Hanlim Pharmaceutical Company Detail

11.12.2 Hanlim Pharmaceutical Business Overview

11.12.3 Hanlim Pharmaceutical Specific Antiviral Drugs for COVID-19 Introduction

11.12.4 Hanlim Pharmaceutical Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)

11.12.5 Hanlim Pharmaceutical Recent Development

11.13 Bristol Laboratories

11.13.1 Bristol Laboratories Company Detail

11.13.2 Bristol Laboratories Business Overview

11.13.3 Bristol Laboratories Specific Antiviral Drugs for COVID-19 Introduction

11.13.4 Bristol Laboratories Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)

11.13.5 Bristol Laboratories Recent Development

11.14 Bayer

11.14.1 Bayer Company Detail

11.14.2 Bayer Business Overview

11.14.3 Bayer Specific Antiviral Drugs for COVID-19 Introduction

11.14.4 Bayer Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)

11.14.5 Bayer Recent Development

11.15 Rising Pharmaceutical

11.15.1 Rising Pharmaceutical Company Detail

11.15.2 Rising Pharmaceutical Business Overview

11.15.3 Rising Pharmaceutical Specific Antiviral Drugs for COVID-19 Introduction

11.15.4 Rising Pharmaceutical Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)

11.15.5 Rising Pharmaceutical Recent Development

11.16 Shanghai Pharma

11.16.1 Shanghai Pharma Company Detail

11.16.2 Shanghai Pharma Business Overview

11.16.3 Shanghai Pharma Specific Antiviral Drugs for COVID-19 Introduction

11.16.4 Shanghai Pharma Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)

11.16.5 Shanghai Pharma Recent Development

11.17 Sichuan Sunny Hope

11.17.1 Sichuan Sunny Hope Company Detail

11.17.2 Sichuan Sunny Hope Business Overview

11.17.3 Sichuan Sunny Hope Specific Antiviral Drugs for COVID-19 Introduction

11.17.4 Sichuan Sunny Hope Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)

11.17.5 Sichuan Sunny Hope Recent Development

11.18 Guangzhou Baiyunshan Guanghua Pharmaceutical

11.18.1 Guangzhou Baiyunshan Guanghua Pharmaceutical Company Detail

11.18.2 Guangzhou Baiyunshan Guanghua Pharmaceutical Business Overview

11.18.3 Guangzhou Baiyunshan Guanghua Pharmaceutical Specific Antiviral Drugs for COVID-19 Introduction

11.18.4 Guangzhou Baiyunshan Guanghua Pharmaceutical Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)

11.18.5 Guangzhou Baiyunshan Guanghua Pharmaceutical Recent Development

11.19 CSPC Group

11.19.1 CSPC Group Company Detail

11.19.2 CSPC Group Business Overview

11.19.3 CSPC Group Specific Antiviral Drugs for COVID-19 Introduction

11.19.4 CSPC Group Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)

11.19.5 CSPC Group Recent Development

11.20 KPC Group

11.20.1 KPC Group Company Detail

11.20.2 KPC Group Business Overview

11.20.3 KPC Group Specific Antiviral Drugs for COVID-19 Introduction

11.20.4 KPC Group Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)

11.20.5 KPC Group Recent Development

11.21 Jinghua Pharmaceutical Group

11.21.1 Jinghua Pharmaceutical Group Company Detail

11.21.2 Jinghua Pharmaceutical Group Business Overview

11.21.3 Jinghua Pharmaceutical Group Specific Antiviral Drugs for COVID-19 Introduction

11.21.4 Jinghua Pharmaceutical Group Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)

11.21.5 Jinghua Pharmaceutical Group Recent Development

11.22 Zhongsheng Pharma

11.22.1 Zhongsheng Pharma Company Detail

11.22.2 Zhongsheng Pharma Business Overview

11.22.3 Zhongsheng Pharma Specific Antiviral Drugs for COVID-19 Introduction

11.22.4 Zhongsheng Pharma Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)

11.22.5 Zhongsheng Pharma Recent Development

11.23 North China Pharmaceutical Group

11.23.1 North China Pharmaceutical Group Company Detail

11.23.2 North China Pharmaceutical Group Business Overview

11.23.3 North China Pharmaceutical Group Specific Antiviral Drugs for COVID-19 Introduction

11.23.4 North China Pharmaceutical Group Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)

11.23.5 North China Pharmaceutical Group Recent Development

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List of Tables

    Table 1. Global Specific Antiviral Drugs for COVID-19 Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029

    Table 2. Key Players of Tablet

    Table 3. Key Players of Injection

    Table 4. Global Specific Antiviral Drugs for COVID-19 Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029

    Table 5. Global Specific Antiviral Drugs for COVID-19 Market Size by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 6. Global Specific Antiviral Drugs for COVID-19 Market Size by Region (2018-2023) & (US$ Million)

    Table 7. Global Specific Antiviral Drugs for COVID-19 Market Share by Region (2018-2023)

    Table 8. Global Specific Antiviral Drugs for COVID-19 Forecasted Market Size by Region (2024-2029) & (US$ Million)

    Table 9. Global Specific Antiviral Drugs for COVID-19 Market Share by Region (2024-2029)

    Table 10. Specific Antiviral Drugs for COVID-19 Market Trends

    Table 11. Specific Antiviral Drugs for COVID-19 Market Drivers

    Table 12. Specific Antiviral Drugs for COVID-19 Market Challenges

    Table 13. Specific Antiviral Drugs for COVID-19 Market Restraints

    Table 14. Global Specific Antiviral Drugs for COVID-19 Revenue by Players (2018-2023) & (US$ Million)

    Table 15. Global Specific Antiviral Drugs for COVID-19 Market Share by Players (2018-2023)

    Table 16. Global Top Specific Antiviral Drugs for COVID-19 Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Specific Antiviral Drugs for COVID-19 as of 2022)

    Table 17. Ranking of Global Top Specific Antiviral Drugs for COVID-19 Companies by Revenue (US$ Million) in 2022

    Table 18. Global 5 Largest Players Market Share by Specific Antiviral Drugs for COVID-19 Revenue (CR5 and HHI) & (2018-2023)

    Table 19. Key Players Headquarters and Area Served

    Table 20. Key Players Specific Antiviral Drugs for COVID-19 Product Solution and Service

    Table 21. Date of Enter into Specific Antiviral Drugs for COVID-19 Market

    Table 22. Mergers & Acquisitions, Expansion Plans

    Table 23. Global Specific Antiviral Drugs for COVID-19 Market Size by Type (2018-2023) & (US$ Million)

    Table 24. Global Specific Antiviral Drugs for COVID-19 Revenue Market Share by Type (2018-2023)

    Table 25. Global Specific Antiviral Drugs for COVID-19 Forecasted Market Size by Type (2024-2029) & (US$ Million)

    Table 26. Global Specific Antiviral Drugs for COVID-19 Revenue Market Share by Type (2024-2029)

    Table 27. Global Specific Antiviral Drugs for COVID-19 Market Size by Application (2018-2023) & (US$ Million)

    Table 28. Global Specific Antiviral Drugs for COVID-19 Revenue Market Share by Application (2018-2023)

    Table 29. Global Specific Antiviral Drugs for COVID-19 Forecasted Market Size by Application (2024-2029) & (US$ Million)

    Table 30. Global Specific Antiviral Drugs for COVID-19 Revenue Market Share by Application (2024-2029)

    Table 31. North America Specific Antiviral Drugs for COVID-19 Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 32. North America Specific Antiviral Drugs for COVID-19 Market Size by Country (2018-2023) & (US$ Million)

    Table 33. North America Specific Antiviral Drugs for COVID-19 Market Size by Country (2024-2029) & (US$ Million)

    Table 34. Europe Specific Antiviral Drugs for COVID-19 Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 35. Europe Specific Antiviral Drugs for COVID-19 Market Size by Country (2018-2023) & (US$ Million)

    Table 36. Europe Specific Antiviral Drugs for COVID-19 Market Size by Country (2024-2029) & (US$ Million)

    Table 37. Asia-Pacific Specific Antiviral Drugs for COVID-19 Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 38. Asia-Pacific Specific Antiviral Drugs for COVID-19 Market Size by Region (2018-2023) & (US$ Million)

    Table 39. Asia-Pacific Specific Antiviral Drugs for COVID-19 Market Size by Region (2024-2029) & (US$ Million)

    Table 40. Latin America Specific Antiviral Drugs for COVID-19 Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 41. Latin America Specific Antiviral Drugs for COVID-19 Market Size by Country (2018-2023) & (US$ Million)

    Table 42. Latin America Specific Antiviral Drugs for COVID-19 Market Size by Country (2024-2029) & (US$ Million)

    Table 43. Middle East & Africa Specific Antiviral Drugs for COVID-19 Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 44. Middle East & Africa Specific Antiviral Drugs for COVID-19 Market Size by Country (2018-2023) & (US$ Million)

    Table 45. Middle East & Africa Specific Antiviral Drugs for COVID-19 Market Size by Country (2024-2029) & (US$ Million)

    Table 46. Sanofi Company Detail

    Table 47. Sanofi Business Overview

    Table 48. Sanofi Specific Antiviral Drugs for COVID-19 Product

    Table 49. Sanofi Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023) & (US$ Million)

    Table 50. Sanofi Recent Development

    Table 51. Novartis Company Detail

    Table 52. Novartis Business Overview

    Table 53. Novartis Specific Antiviral Drugs for COVID-19 Product

    Table 54. Novartis Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023) & (US$ Million)

    Table 55. Novartis Recent Development

    Table 56. Shanghai Zhongxisanwei Company Detail

    Table 57. Shanghai Zhongxisanwei Business Overview

    Table 58. Shanghai Zhongxisanwei Specific Antiviral Drugs for COVID-19 Product

    Table 59. Shanghai Zhongxisanwei Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023) & (US$ Million)

    Table 60. Shanghai Zhongxisanwei Recent Development

    Table 61. Teva Company Detail

    Table 62. Teva Business Overview

    Table 63. Teva Specific Antiviral Drugs for COVID-19 Product

    Table 64. Teva Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023) & (US$ Million)

    Table 65. Teva Recent Development

    Table 66. Zydus Cadila Company Detail

    Table 67. Zydus Cadila Business Overview

    Table 68. Zydus Cadila Specific Antiviral Drugs for COVID-19 Product

    Table 69. Zydus Cadila Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023) & (US$ Million)

    Table 70. Zydus Cadila Recent Development

    Table 71. Mylan Company Detail

    Table 72. Mylan Business Overview

    Table 73. Mylan Specific Antiviral Drugs for COVID-19 Product

    Table 74. Mylan Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023) & (US$ Million)

    Table 75. Mylan Recent Development

    Table 76. Apotex Company Detail

    Table 77. Apotex Business Overview

    Table 78. Apotex Specific Antiviral Drugs for COVID-19 Product

    Table 79. Apotex Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023) & (US$ Million)

    Table 80. Apotex Recent Development

    Table 81. Advanz Pharma Company Detail

    Table 82. Advanz Pharma Business Overview

    Table 83. Advanz Pharma Specific Antiviral Drugs for COVID-19 Product

    Table 84. Advanz Pharma Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023) & (US$ Million)

    Table 85. Advanz Pharma Recent Development

    Table 86. Sun Pharma Company Detail

    Table 87. Sun Pharma Business Overview

    Table 88. Sun Pharma Specific Antiviral Drugs for COVID-19 Product

    Table 89. Sun Pharma Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023) & (US$ Million)

    Table 90. Sun Pharma Recent Development

    Table 91. Kyung Poong Company Detail

    Table 92. Kyung Poong Business Overview

    Table 93. Kyung Poong Specific Antiviral Drugs for COVID-19 Product

    Table 94. Kyung Poong Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023) & (US$ Million)

    Table 95. Kyung Poong Recent Development

    Table 96. Ipca Laboratories Company Detail

    Table 97. Ipca Laboratories Business Overview

    Table 98. Ipca Laboratories Specific Antiviral Drugs for COVID-19 Product

    Table 99. Ipca Laboratories Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023) & (US$ Million)

    Table 100. Ipca Laboratories Recent Development

    Table 101. Hanlim Pharmaceutical Company Detail

    Table 102. Hanlim Pharmaceutical Business Overview

    Table 103. Hanlim Pharmaceutical Specific Antiviral Drugs for COVID-19 Product

    Table 104. Hanlim Pharmaceutical Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023) & (US$ Million)

    Table 105. Hanlim Pharmaceutical Recent Development

    Table 106. Bristol Laboratories Company Detail

    Table 107. Bristol Laboratories Business Overview

    Table 108. Bristol Laboratories Specific Antiviral Drugs for COVID-19 Product

    Table 109. Bristol Laboratories Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023) & (US$ Million)

    Table 110. Bristol Laboratories Recent Development

    Table 111. Bayer Company Detail

    Table 112. Bayer Business Overview

    Table 113. Bayer Specific Antiviral Drugs for COVID-19 Product

    Table 114. Bayer Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023) & (US$ Million)

    Table 115. Bayer Recent Development

    Table 116. Rising Pharmaceutical Company Detail

    Table 117. Rising Pharmaceutical Business Overview

    Table 118. Rising Pharmaceutical Specific Antiviral Drugs for COVID-19 Product

    Table 119. Rising Pharmaceutical Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023) & (US$ Million)

    Table 120. Rising Pharmaceutical Recent Development

    Table 121. Shanghai Pharma Company Detail

    Table 122. Shanghai Pharma Business Overview

    Table 123. Shanghai Pharma Specific Antiviral Drugs for COVID-19 Product

    Table 124. Shanghai Pharma Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023) & (US$ Million)

    Table 125. Shanghai Pharma Recent Development

    Table 126. Sichuan Sunny Hope Company Detail

    Table 127. Sichuan Sunny Hope Business Overview

    Table 128. Sichuan Sunny Hope Specific Antiviral Drugs for COVID-19 Product

    Table 129. Sichuan Sunny Hope Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023) & (US$ Million)

    Table 130. Sichuan Sunny Hope Recent Development

    Table 131. Guangzhou Baiyunshan Guanghua Pharmaceutical Company Detail

    Table 132. Guangzhou Baiyunshan Guanghua Pharmaceutical Business Overview

    Table 133. Guangzhou Baiyunshan Guanghua Pharmaceutical Specific Antiviral Drugs for COVID-19 Product

    Table 134. Guangzhou Baiyunshan Guanghua Pharmaceutical Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023) & (US$ Million)

    Table 135. Guangzhou Baiyunshan Guanghua Pharmaceutical Recent Development

    Table 136. CSPC Group Company Detail

    Table 137. CSPC Group Business Overview

    Table 138. CSPC Group Specific Antiviral Drugs for COVID-19 Product

    Table 139. CSPC Group Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023) & (US$ Million)

    Table 140. CSPC Group Recent Development

    Table 141. KPC Group Company Detail

    Table 142. KPC Group Business Overview

    Table 143. KPC Group Specific Antiviral Drugs for COVID-19 Product

    Table 144. KPC Group Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023) & (US$ Million)

    Table 145. KPC Group Recent Development

    Table 146. Jinghua Pharmaceutical Group Company Detail

    Table 147. Jinghua Pharmaceutical Group Business Overview

    Table 148. Jinghua Pharmaceutical Group Specific Antiviral Drugs for COVID-19 Product

    Table 149. Jinghua Pharmaceutical Group Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023) & (US$ Million)

    Table 150. Jinghua Pharmaceutical Group Recent Development

    Table 151. Zhongsheng Pharma Company Detail

    Table 152. Zhongsheng Pharma Business Overview

    Table 153. Zhongsheng Pharma Specific Antiviral Drugs for COVID-19 Product

    Table 154. Zhongsheng Pharma Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023) & (US$ Million)

    Table 155. Zhongsheng Pharma Recent Development

    Table 156. North China Pharmaceutical Group Company Detail

    Table 157. North China Pharmaceutical Group Business Overview

    Table 158. North China Pharmaceutical Group Specific Antiviral Drugs for COVID-19 Product

    Table 159. North China Pharmaceutical Group Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023) & (US$ Million)

    Table 160. North China Pharmaceutical Group Recent Development

    Table 161. Research Programs/Design for This Report

    Table 162. Key Data Information from Secondary Sources

    Table 163. Key Data Information from Primary Sources

List of Figures

    Figure 1. Global Specific Antiviral Drugs for COVID-19 Market Size Comparison by Type (2023-2029) & (US$ Million)

    Figure 2. Global Specific Antiviral Drugs for COVID-19 Market Share by Type: 2022 VS 2029

    Figure 3. Tablet Features

    Figure 4. Injection Features

    Figure 5. Global Specific Antiviral Drugs for COVID-19 Market Size Comparison by Application (2023-2029) & (US$ Million)

    Figure 6. Global Specific Antiviral Drugs for COVID-19 Market Share by Application: 2022 VS 2029

    Figure 7. Mild Symptom Patient Case Studies

    Figure 8. Critically Ill Patient Case Studies

    Figure 9. Specific Antiviral Drugs for COVID-19 Report Years Considered

    Figure 10. Global Specific Antiviral Drugs for COVID-19 Market Size (US$ Million), Year-over-Year: 2018-2029

    Figure 11. Global Specific Antiviral Drugs for COVID-19 Market Size, (US$ Million), 2018 VS 2022 VS 2029

    Figure 12. Global Specific Antiviral Drugs for COVID-19 Market Share by Region: 2022 VS 2029

    Figure 13. Global Specific Antiviral Drugs for COVID-19 Market Share by Players in 2022

    Figure 14. Global Top Specific Antiviral Drugs for COVID-19 Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Specific Antiviral Drugs for COVID-19 as of 2022)

    Figure 15. The Top 10 and 5 Players Market Share by Specific Antiviral Drugs for COVID-19 Revenue in 2022

    Figure 16. North America Specific Antiviral Drugs for COVID-19 Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 17. North America Specific Antiviral Drugs for COVID-19 Market Share by Country (2018-2029)

    Figure 18. United States Specific Antiviral Drugs for COVID-19 Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 19. Canada Specific Antiviral Drugs for COVID-19 Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 20. Europe Specific Antiviral Drugs for COVID-19 Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 21. Europe Specific Antiviral Drugs for COVID-19 Market Share by Country (2018-2029)

    Figure 22. Germany Specific Antiviral Drugs for COVID-19 Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 23. France Specific Antiviral Drugs for COVID-19 Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 24. U.K. Specific Antiviral Drugs for COVID-19 Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 25. Italy Specific Antiviral Drugs for COVID-19 Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 26. Russia Specific Antiviral Drugs for COVID-19 Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 27. Nordic Countries Specific Antiviral Drugs for COVID-19 Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 28. Asia-Pacific Specific Antiviral Drugs for COVID-19 Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 29. Asia-Pacific Specific Antiviral Drugs for COVID-19 Market Share by Region (2018-2029)

    Figure 30. China Specific Antiviral Drugs for COVID-19 Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 31. Japan Specific Antiviral Drugs for COVID-19 Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 32. South Korea Specific Antiviral Drugs for COVID-19 Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 33. Southeast Asia Specific Antiviral Drugs for COVID-19 Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 34. India Specific Antiviral Drugs for COVID-19 Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 35. Australia Specific Antiviral Drugs for COVID-19 Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 36. Latin America Specific Antiviral Drugs for COVID-19 Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 37. Latin America Specific Antiviral Drugs for COVID-19 Market Share by Country (2018-2029)

    Figure 38. Mexico Specific Antiviral Drugs for COVID-19 Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 39. Brazil Specific Antiviral Drugs for COVID-19 Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 40. Middle East & Africa Specific Antiviral Drugs for COVID-19 Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 41. Middle East & Africa Specific Antiviral Drugs for COVID-19 Market Share by Country (2018-2029)

    Figure 42. Turkey Specific Antiviral Drugs for COVID-19 Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 43. Saudi Arabia Specific Antiviral Drugs for COVID-19 Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 44. Sanofi Revenue Growth Rate in Specific Antiviral Drugs for COVID-19 Business (2018-2023)

    Figure 45. Novartis Revenue Growth Rate in Specific Antiviral Drugs for COVID-19 Business (2018-2023)

    Figure 46. Shanghai Zhongxisanwei Revenue Growth Rate in Specific Antiviral Drugs for COVID-19 Business (2018-2023)

    Figure 47. Teva Revenue Growth Rate in Specific Antiviral Drugs for COVID-19 Business (2018-2023)

    Figure 48. Zydus Cadila Revenue Growth Rate in Specific Antiviral Drugs for COVID-19 Business (2018-2023)

    Figure 49. Mylan Revenue Growth Rate in Specific Antiviral Drugs for COVID-19 Business (2018-2023)

    Figure 50. Apotex Revenue Growth Rate in Specific Antiviral Drugs for COVID-19 Business (2018-2023)

    Figure 51. Advanz Pharma Revenue Growth Rate in Specific Antiviral Drugs for COVID-19 Business (2018-2023)

    Figure 52. Sun Pharma Revenue Growth Rate in Specific Antiviral Drugs for COVID-19 Business (2018-2023)

    Figure 53. Kyung Poong Revenue Growth Rate in Specific Antiviral Drugs for COVID-19 Business (2018-2023)

    Figure 54. Ipca Laboratories Revenue Growth Rate in Specific Antiviral Drugs for COVID-19 Business (2018-2023)

    Figure 55. Hanlim Pharmaceutical Revenue Growth Rate in Specific Antiviral Drugs for COVID-19 Business (2018-2023)

    Figure 56. Bristol Laboratories Revenue Growth Rate in Specific Antiviral Drugs for COVID-19 Business (2018-2023)

    Figure 57. Bayer Revenue Growth Rate in Specific Antiviral Drugs for COVID-19 Business (2018-2023)

    Figure 58. Rising Pharmaceutical Revenue Growth Rate in Specific Antiviral Drugs for COVID-19 Business (2018-2023)

    Figure 59. Shanghai Pharma Revenue Growth Rate in Specific Antiviral Drugs for COVID-19 Business (2018-2023)

    Figure 60. Sichuan Sunny Hope Revenue Growth Rate in Specific Antiviral Drugs for COVID-19 Business (2018-2023)

    Figure 61. Guangzhou Baiyunshan Guanghua Pharmaceutical Revenue Growth Rate in Specific Antiviral Drugs for COVID-19 Business (2018-2023)

    Figure 62. CSPC Group Revenue Growth Rate in Specific Antiviral Drugs for COVID-19 Business (2018-2023)

    Figure 63. KPC Group Revenue Growth Rate in Specific Antiviral Drugs for COVID-19 Business (2018-2023)

    Figure 64. Jinghua Pharmaceutical Group Revenue Growth Rate in Specific Antiviral Drugs for COVID-19 Business (2018-2023)

    Figure 65. Zhongsheng Pharma Revenue Growth Rate in Specific Antiviral Drugs for COVID-19 Business (2018-2023)

    Figure 66. North China Pharmaceutical Group Revenue Growth Rate in Specific Antiviral Drugs for COVID-19 Business (2018-2023)

    Figure 67. Bottom-up and Top-down Approaches for This Report

    Figure 68. Data Triangulation

    Figure 69. Key Executives Interviewed